Despite the low incidence of venous thromboembolism (VTE) in vWD patients receiving vWF replacement, the risk is not negligible, particularly in patients with additional risk factors such as obesity, advanced age, or estrogen use. This evidence concerns the gene VWF and obesity due to melanocortin 4 receptor deficiency.